Effects of a Reduced Dose Schedule and Intramuscular Administration of Anthrax Vaccine Adsorbed on Immunogenicity and Safety at 7 MonthsA Randomized Trial
Open Access
- 1 October 2008
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 300 (13) , 1532-1543
- https://doi.org/10.1001/jama.300.13.1532
Abstract
Simpler and better tolerated regimens for vaccination with anthrax vaccine adsorbed (AVA) are needed. Anthrax vaccine adsorbed (BioThrax, Emergent BioSolutions Inc, Lansing, Michigan) is currently the only licensed anthrax vaccine in the United States and the only licensed aluminum-adjuvant vaccine administered subcutaneously (SQ).1-3 The principal immunogen of AVA is the anthrax toxin component protective antigen (PA).4 The licensed AVA vaccination regimen consists of 0.5-mL SQ injections at 0, 2, and 4 weeks and 6, 12, and 18 months with annual boosters thereafter. Data supporting the licensed regimen are limited and originate from animal studies and a single field evaluation of a human vaccination.5,6Keywords
This publication has 1 reference indexed in Scilit:
- Faculty Opinions recommendation of Multiple imputation of missing blood pressure covariates in survival analysis.Published by H1 Connect ,2008